How to improve low lymph node recovery rates from axillary clearance specimens of breast cancer. A short term audit

Gábor Cserni

Abstract

Aim—To implement an audit scheme to increase the lymph node yield from axillary clearance specimens.

Methods—Two pathologists cut up each specimen after weighing it. The number of nodes and the dimensions of the largest and smallest nodes were recorded, together with the number of non-lymph node structures recovered. Fifty consecutive audited cases were compared with 50 consecutive cases assessed before the audit process.

Results—It proved possible to increase the median number of lymph nodes from 10 to 22. There was an obvious learning period, during which the number of nodes recovered during the second pathologist’s cut-up gradually decreased, while the total number remained relatively constant. The increase in lymph node yield resulted from the recovery of smaller nodes. The identification of lymph nodes also improved, and fewer non-lymph node structures were recovered by the end of the study.

Conclusions—Such an audit scheme can be recommended for all institutions where the lymph node yield of axillary clearance specimens seems suboptimal. The relevance of recovering more nodes remains to be determined; from this small series, it seems to have no clinical impact.

(J Clin Pathol 1998;51:846–849)

Keywords: audit; axillary clearance; histopathology; lymph node recovery

The use of axillary surgery in the treatment of breast cancer remains controversial. Axillary clearance (total or level I-II dissection), axillary sampling, sentinel node biopsy, or omission of axillary surgery with or without irradiation to the axilla are practised in different settings, but no consensus exists. There is no doubt that all removed lymph nodes must be examined histologically, since the lymph node status is the most powerful single prognostic factor and has a significant impact on the further treatment of the patient.

It is widely accepted that a minimum of 10 lymph nodes per axillary clearance specimen must be examined for an adequate assessment of the axillary lymph node status. The number of lymph nodes examined by the histopathologist depends on (1) anatomical differences, (2) the diligence of the surgeon in recovering the nodes from the axilla, and (3) the diligence of the pathologist in recovering lymph nodes from the dissection specimen.

The first of these factors is obvious. The second has been audited and found to make a contribution to a lower recovery rate in up to 38% of the clearance procedures, but to only a minor degree. Our necropsy experience supports this.

The number of pathologically assessed lymph nodes varies greatly from institution to institution, with the median number of lymph nodes per axilla ranging from eight to 28. I made a retrospective study of the numbers of lymph nodes histopathologically assessed between 1980 and 1996. Despite a gradual increase in the number of nodes recovered, I found that approximately three quarters of all the specimens contained fewer than 10 lymph nodes, the median number of nodes recovered in recent years being nine per axilla. This is comparable with the experience in some other institutions, but seems suboptimal in view of the recommended minimum of 10 nodes.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Audited</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UICC pT category of primary tumour</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pTis</td>
<td>0</td>
<td>1</td>
<td>&gt;0.6, NS</td>
</tr>
<tr>
<td>pTx</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td>13</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>27</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>pT4</td>
<td>7</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Axillary lymph node status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>23</td>
<td>31</td>
<td>&gt;0.1, NS</td>
</tr>
<tr>
<td>Positive</td>
<td>27</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>1–3 positive</td>
<td>13</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>&gt;3 positive</td>
<td>14</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Number of recovered lymph nodes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>10.6</td>
<td>23.56</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median</td>
<td>10</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>4–39</td>
<td>11–42</td>
<td></td>
</tr>
<tr>
<td>Smallest lymph node dimension (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>3.09</td>
<td>1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median</td>
<td>2.8</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.5–8.4</td>
<td>0.5–3.8</td>
<td></td>
</tr>
<tr>
<td>Largest lymph node dimension (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>14.78</td>
<td>16.9</td>
<td>&gt;0.05, NS</td>
</tr>
<tr>
<td>Median</td>
<td>14.85</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>8.0–23.2</td>
<td>7–45</td>
<td></td>
</tr>
<tr>
<td>Number of “non-lymph-nodes”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1.5</td>
<td>9.18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0–6</td>
<td>0–30</td>
<td></td>
</tr>
</tbody>
</table>

*Smallest lymph node dimension” refers to the largest dimension of the smallest node.*

Bács-Kiskun County Teaching Hospital, Department of Pathology, Kecskemét, Hungary
G Cserni

Correspondence to: Dr G Cserni, Bács-Kiskun County Teaching Hospital, Department of Pathology, H-6000 Kecskemét, Nyíri út 38, Hungary; email: cserni@freemail.c3.hu

Accepted for publication 28 May 1998
Accordingly, I decided to monitor our lymph node recovery rate and set up audit conditions in 1997.

**Methods**

I audited the recovery rate of 50 consecutive axillary clearance specimens between 23 July and 12 December 1997 and compared the results with those of the 50 specimens immediately preceding those audited, also all processed in 1997; there was thus no overlap with my previous study. The surgical procedure used was identical in the two groups compared: axillary dissection after Cady, combined with level III dissection in the event of clinical involvement.

The formalin fixed or fresh dissection specimens were weighed (a procedure introduced into our cut-up protocol from the beginning of the audit) and cut up, with the aid of simultaneous palpation, into thin parallel sections. Care was taken not to cut through palpable lymph nodes. All nodes were processed separately, but only a part of larger nodes was taken for histology. A second pathologist then assessed the specimen and tried to remove as many further lymph nodes as possible. For the purpose of the audit, only two pathologists shared these duties in rotation, one or other of them always auditing the performance of the other. All lymph nodes were cut in such a manner as to obtain their largest dimension on the histological slides.

The lymph nodes were counted, and the largest dimensions of the largest and smallest nodes were measured with Vernier scales. The number of structures originally thought to represent lymph nodes but microscopically proving to be something else was also recorded.

Statistical comparison between groups was made with the Student t test for parametric data and with the χ² test for categoric data. In comparisons involving the quantitative axillary nodal status of the patients, a prognostic approach was used, the patients being divided into node negative and node positive groups, the latter category being further divided into patients with one to three involved nodes or more than three involved nodes.

**Results**

Most of the clearance specimens weighed between 51 and 100 g. The median number of lymph nodes showed a tendency to increase with increasing axillary fat weight (18, 22, and 30 for the ranges 0–50 g, 51–100 g, and > 100 g, respectively; n = 11, 30, and 9 patients, respectively), but no consistent relation was observed between the two variables.

The study group and the control group did not differ significantly in terms of the tumour pT category, the qualitative or quantitative axillary nodal status, or the largest lymph node dimension, but there was a significant difference between the two groups with regard to the number of lymph nodes, the size of the smallest lymph nodes, and the number of non-lymph-node structures removed as lymph nodes (table 1).

The total number of lymph nodes recovered did not change significantly during the audit process (fig 1), but the number removed by the auditor during the second cut-up gradually decreased (fig 2). The size of the lymph nodes removed by the auditor also showed a gradual decrease (fig 3). The number of non-lymph-node structures reached a maximum in the second group of 10 cases, while the number of non-lymph-node structures recovered during the second cut-up showed a gradual decrease (fig 4). The ratio of the number of non-lymph-node structures to the number of lymph nodes recovered was used.
We initiated an audit process to maximise the lymph node yield from axillary clearance specimens. Although the median number of lymph nodes removed during the second cut-up was 146 (12.4% of all lymph nodes recovered). Only five metastatic nodes were found among these (3.2% of all metastatic nodes). In no instance did the second cut-up alter the qualitative or quantitative axillary lymph node status; the ratio of positive nodes to all nodes changed from 10/19, 18/25, 27/40, and 18/28 to 11/42, 20/33, 28/42, and 19/30 in cases 4, 5, 35, and 50, respectively. All the metastases identified from the second cut-up were micrometastases, ranging in size from 0.7 to 2.0 mm.

**Discussion**

We share the opinion that all submitted lymph nodes should be assessed histologically and that the largest possible lymph node yield should be aimed at in axillary dissection specimens. Our audit proved effective in this respect and I can recommend it for those institutions where lymph node yields are low. However, the clinical impact of assessing an increased number of nodes seems minimal and, if a larger number of cases gives similar results (our ongoing retrospective data collection seems to suggest this), the cost and benefit features accompanying the recovery of more nodes must also be considered.

---

I thank Dr M Tarján for his contribution to the work. The study was supported by the János Bolyai fellowship of the Hungarian Academy of Sciences.


Royal College of Pathologists

Forthcoming Symposia

**Transfusion Medicine Update**
17–18 November 1998

**Cytopathology Update**
17 December 1998

**What to do When the Cause of Death is in the Brain**
27 January 1999

**Antimicrobial Resistance: In Humans and Other Animals**
17 February 1999

**Cytokines and Chemokines in Disease**
18 March 1999

**Can’t Give a Cause of Death—Won’t Give a Cause of Death**
22 April 1999

These meetings will be held at the Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF and are open to members and non-members of the College.

Further details and application forms from the Scientific Meetings Officer, tel +44 (0)171 930 5862, ext 24/25; fax +44 (0)171 321 0523.
How to improve low lymph node recovery rates from axillary clearance specimens of breast cancer. A short-term audit.

G Cserni

doi: 10.1136/jcp.51.11.846

Updated information and services can be found at:
http://jcp.bmj.com/content/51/11/846

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/